Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Imugene ( (AU:IMU) ) has issued an update.
Imugene Limited has announced significant progress in its azer-cel program, with strong clinical data and FDA support to advance to the next trial stage. The company expects to reduce operating costs by 50% in the coming year and has formed a strategic collaboration with JW Therapeutics to leverage commercial CAR T infrastructure. The FDA’s positive feedback on Imugene’s dosing regimen and patient population for azer-cel, along with promising clinical results, positions the company to explore additional registrational opportunities, potentially enhancing its market position and offering new hope for blood cancer patients.
The most recent analyst rating on (AU:IMU) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Imugene stock, see the AU:IMU Stock Forecast page.
More about Imugene
Imugene Limited is a biotechnology company focused on developing innovative cancer immunotherapies. Its primary products include azer-cel, a treatment aimed at blood cancers, and the onCARlytics platform. The company is actively engaged in clinical trials and partnerships, notably with JW Therapeutics, to advance its commercial and clinical objectives.
Average Trading Volume: 2,153,935
Technical Sentiment Signal: Sell
Current Market Cap: A$100.9M
Learn more about IMU stock on TipRanks’ Stock Analysis page.